Brief: Arctic Bioscience Q3 EBITDA Loss Widens To NOK 7.8 Mln

Arctic Bioscience AS

31/10/2022 07:23

Oct 31 (Reuters) - Arctic Bioscience AS  ABSA.OL :
    * Q3 2022 OPERATIONAL UPDATE - POSITIVE PROGRESS IN BOTH
PHARMA
AND NUTRA
    * Q3 REVENUES FROM SALES: NOK 9,3 MILLION (NOK 4,8 MILLION)
    * Q3 EBITDA: NOK -7,8 MILLION (NOK -7,4 MILLION)
    * MAINTAINS EARLIER COMMUNICATED FINANCIAL OUTLOOK OF A Y/Y
REVENUE GROWTH IN 2022 OF 60-70 %, AND A FY EBITDA IN RANGE OF
MNOK -35 TO MNOK -30
    * COMPANY'S LIQUIDITY SITUATION AT END OF YEAR IS EXPECTED
TO BE
STRONG AND EXPECTED TO BE SUFFICIENT TO HANDLE PHARMACEUTICAL
PHASE IIB CLINICAL TRIAL

Source text for Eikon:  ID:nWkr1tP01M 
Further company coverage:  ABSA.OL 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))